Beyond ocrelizumab in primary progressive multiple sclerosis

Thomas Williams¹, Jeremy Chataway^{2

3}

Affiliations

¹ Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK. thomas.e.williams@ucl.ac.uk.
² Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
³ National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK.

Comment

Thomas Williams et al. Nat Rev Neurol. 2022 Nov.

. 2022 Nov;18(11):641-642.

doi: 10.1038/s41582-022-00724-8.

Thomas Williams¹, Jeremy Chataway^{2

3}

¹ Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK. thomas.e.williams@ucl.ac.uk.
² Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
³ National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK.

No abstract available

Comment on

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
Portaccio E, Fonderico M, Iaffaldano P, Pastò L, Razzolini L, Bellinvia A, De Luca G, Ragonese P, Patti F, Brescia Morra V, Cocco E, Sola P, Inglese M, Lus G, Pozzilli C, Maimone D, Lugaresi A, Gazzola P, Comi G, Pesci I, Spitaleri D, Rezzonico M, Vianello M, Avolio C, Logullo FO, Granella F, Salvetti M, Zaffaroni M, Lucisano G, Filippi M, Trojano M, Amato MP; Italian Multiple Sclerosis Register Centers Group. Portaccio E, et al. JAMA Neurol. 2022 Sep 1;79(9):869-878. doi: 10.1001/jamaneurol.2022.1929. JAMA Neurol. 2022. PMID: 35877104 Free PMC article. Clinical Trial.

1. Hauser, S. L. & Cree, B. A. C. Treatment of multiple sclerosis: a review. Am. J. Med. 133, 1380–1390.e2 (2020). - DOI
1. Montalban, X. et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N. Engl. J. Med. 376, 209–220 (2017). - DOI
1. European Medicines Agency. Summary of Opinion EMA: Ocrevus (ocrelizumab) https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus (2017).
1. Portaccio, E. et al. Disease-modifying treatments and time to loss of ambulatory function in patients with primary progressive multiple sclerosis. JAMA Neurol. https://doi.org/10.1001/jamaneurol.2022.1929 (2022). - DOI - PubMed
1. Brown, J. W. L. et al. Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis. J. Am. Med. Assoc. 321, 175–187 (2019). - DOI